Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest Enters Market For BRCA Gene Testing

This article was originally published in The Gray Sheet

Executive Summary

With the Oct. 15 launch of the BRCAvantage genetic test, Quest Diagnostics Inc. became the latest entrant into the now-competitive marketplace for BRCA diagnostic testing for the likelihood of inheriting breast or ovarian cancer.

Advertisement

Related Content

BRCA Reimbursement Cut Heightens Tensions Between CMS And Lab Industry
Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market
News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
News Briefs: Approvals For Abbott’s MitraClip, Allergan’s Juvéderm; Diagnostics News
Myriad Wields Proprietary Database To Protect Testing Market
News Briefs: Device Tax Repeal Update; Surgery Firms Merge; Medtronic’s Drug-Eluting Balloon
Diagnostic Companies Rush To Test Formerly Off-Limit Genes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032517

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel